ITA0499
ITA0499
- Catalog: ITA0499
- Gene/Protein: ELOVL1
- Product Description: Immunotag™ ELOVL1 Antibody
385.0000
Price in reward points: 385
| Antibody Specification | |
| Datasheet |
|
| Target Protein | ELOVL1 |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,IF/ICC,ELISA |
| Recommended Dilution | WB 1:500-1:2000, IF/ICC 1:100-1:500 |
| Concentration | 1 mg/ml |
| Reactive Species | Human,Mouse |
| Host Species | Rabbit |
| Immunogen | A synthesized peptide derived from human ELOVL1 |
| Specificity | ELOVL1 Antibody detects endogenous levels of ELOVL1 |
| Purification | The antiserum was purified by peptide affinity chromatography. |
| Form | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.Store at -20 °C.Stable for 12 months from date of receipt |
| Gene Name | ELOVL1 |
| Accession No. | Q9BW60 |
| Alternate Names | 3 keto acyl CoA synthase ELOVL1; 3-keto acyl-CoA synthase ELOVL1; CGI 88; Elongation of very long chain fatty acids (FEN1/Elo2 SUR4/Elo3 yeast) like 1; Elongation of very long chain fatty acids like 1; Elongation of very long chain fatty acids protein 1; ELOV1_HUMAN; ELOVL 1; ELOVL FA elongase 1; ELOVL fatty acid elongase 1; ELOVL1; Ssc1; Ssc1, mouse, homolog of; very long chain 3 oxoacyl CoA synthase 1; Very-long-chain 3-oxoacyl-CoA synthase 1; |
| Description | Catalyzes the first and rate-limiting reaction of the four that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process, allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids/VLCFAs per cycle. Condensing enzyme that exhibits activity toward saturated C18 to C26 acyl-CoA substrates, with the highest activity towards C22:0 acyl-CoA. May participate in the production of both saturated and monounsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. Important for saturated C24:0 and monounsaturated C24:1 sphingolipid synthesis. Indirectly inhibits RPE65 via production of VLCFAs. |
| Cell Pathway/ Category | Primary Polyclonal Antibody |
| Protein MW | 35kDa |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |
| Material Safety Data Sheet | |
| English_US |
|
| Danish |
|
| Dutch |
|
| English_UK |
|
| French |
|
| German |
|
| Spanish |
|
| Norwegian |
|
| Portuguese |
|
| Finnish |
|
| Swedish |
|
| Polish |
|